HeimSNPHY • OTCMKTS
add
Santen Pharmaceutical ADR Representing Ord Shs
Við síðustu lokun
11,01 $
Dagbil
11,00 $ - 11,46 $
Árabil
8,95 $ - 13,00 $
Markaðsvirði
616,91 ma. JPY
Meðalmagn
4,70 þ.
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (JPY) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 71,63 ma. | -2,43% |
Rekstrarkostnaður | 29,41 ma. | -7,03% |
Nettótekjur | 8,14 ma. | -8,21% |
Hagnaðarhlutfall | 11,36 | -5,96% |
Hagnaður á hvern hlut | — | — |
EBITDA | 15,05 ma. | -12,75% |
Virkt skatthlutfall | 22,06% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (JPY) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 84,44 ma. | 30,46% |
Heildareignir | 409,08 ma. | -4,19% |
Heildarskuldir | 120,83 ma. | 0,25% |
Eigið fé alls | 288,25 ma. | — |
Útistandandi hlutabréf | 349,15 m. | — |
Eiginfjárgengi | 0,01 | — |
Arðsemi eigna | 6,35% | — |
Ávöxtun eigin fjár | 9,02% | — |
Peningaflæði
Breyting á handbæru fé
| (JPY) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 8,14 ma. | -8,21% |
Handbært fé frá rekstri | 16,17 ma. | -35,81% |
Reiðufé frá fjárfestingum | -3,46 ma. | -219,37% |
Reiðufé frá fjármögnun | -13,29 ma. | -125,23% |
Breyting á handbæru fé | -5,30 ma. | -127,59% |
Frjálst peningaflæði | 11,24 ma. | -49,67% |
Um
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.
The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
Framkvæmdastjóri
Stofnsett
1890
Höfuðstöðvar
Vefsvæði
Starfsfólk
3.744
